Protective effects of extendin‑4 on hypoxia/reoxygenation‑induced injury in H9c2 cells Corrigendum in /10.3892/mmr.2020.11159

Lu,Kai; Chang,Guanglei; Ye,Lin; Zhang,Peng; Li,Yong; Zhang,Dongying

doi:10.3892/mmr.2015.3682

Protective effects of extendin‑4 on hypoxia/reoxygenation‑induced injury in H9c2 cells

Corrigendum in: /10.3892/mmr.2020.11159

Authors:
- Kai Lu
- Guanglei Chang
- Lin Ye
- Peng Zhang
- Yong Li
- Dongying Zhang
View Affiliations

Affiliations: Department of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P.R. China, Center for Perinatal Biology, Division of Pharmacology, Department of Basic Sciences, Loma Linda University School of Medicine, Loma Linda, CA 92350, USA
Published online on: April 24, 2015 https://doi.org/10.3892/mmr.2015.3682
Pages: 3007-3016

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Glucagon-like peptide-1 (GLP-1) analogues are likely to exert cardioprotective effects via balancing the energy metabolism in cardiomyocytes following ischemic or hypoxic insults. The present study aimed to explore the protective effects and mechanism of exendin‑4, a GLP‑1 analogue, on cardiomyocyte glucose uptake using an in vitro model of hypoxia/reoxygenation (H/R) of H9c2 cardiomyocyte cells. Pre‑treatment with exendin‑4 (200 nM) prior to H/R increased the cell viability, decreased cell apoptosis, enhanced cardiomyocyte glucose uptake and increased the production of adenosine triphosphate. Exendin‑4 also decreased the levels of lactate dehydrogenase and creatine kinase‑MB in the culture medium. Furthermore, the activity of carnitine palmitoyltransferase‑1 in the H9c2 cells was decreased, while the activity of phosphofructokinase‑1 was increased following exendin‑4 treatment. Moreover, pre‑treatment with exendin‑4 increased the expression of p38 mitogen‑activated protein kinase (p38MAPK) γ and translocation of glucose transporter‑1 in H9c2 cells subjected to H/R. However, these effects were attenuated by the p38MAPK inhibitors BIRB796 and SB203580. The results suggested that exendin‑4 exerted significant cardioprotective effects against H/R‑induced cell injury and restored the metabolic imbalance of cardiomyocytes by activating the p38MAPK signaling pathway in the H9c2 cell model. Importantly, p38MAPKγ, one subunit of p38MAPK, may have the most important function in this process. The results of the present study may be helpful in the development of novel drugs to treat patients with coronary heart disease.

View Figures

View References

1	Hütter JF and Soboll S: Role of fatty acid metabolites in the development of myocardial ischemic damage. Int J Biochem. 24:399–403. 1992. View Article : Google Scholar : PubMed/NCBI
2	Gambert S, Vergely C, Filomenko R, Moreau D, Bettaieb A, Opie LH and Rochette L: Adverse effects of free fatty acid associated with increased oxidative stress in postischemic isolated rat hearts. Mol Cell Biochem. 283:147–152. 2006. View Article : Google Scholar : PubMed/NCBI
3	Grynberg A: Effectors of fatty acid oxidation reduction: Promising new anti-ischaemic agents. Curr Pharm Des. 11:489–509. 2005. View Article : Google Scholar : PubMed/NCBI
4	Avogaro A: Cardioprotective effects of glucagon-like peptide-1: Preclinical and clinical data. G Ital Cardiol (Rome). 12(Suppl 2): 17–24. 2011.In Italian.
5	Otto-Buczkowska E: Glucagon and glucagon-like peptides the role in control glucose homeostasis. Part I. Pediatr Endocrinol Diabetes Metab. 17:215–221. 2011.In Polish.
6	Gallwitz B: Anorexigenic effects of GLP-1 and its analogues. Handb Exp Pharmacol. 209:185–207. 2012.PubMed/NCBI
7	Quintanilla-García C and Zúñiga-Guajardo S: The incretin effect and type 2 diabetes. Rev Med Inst Mex Seguro Soc. 48:509–520. 2010.In Spanish.
8	Lindamood CA and Taylor JR: Emerging new therapies for the treatment of type 2 diabetes mellitus: Glucagon-like peptide-1 receptor agonists. Clin Ther. Feb 3–2015.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI
9	Harris KB and McCarty DJ: Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus. Ther Adv Endocrinol Metab. 6:3–18. 2015. View Article : Google Scholar : PubMed/NCBI
10	Bao W, Aravindhan K, Alsaid H, Chendrimada T, Szapacs M, Citerone DR, Harpel MR, Willette RN, Lepore JJ and Jucker BM: Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: Evidence for improving cardiac metabolic efficiency. PLoS One. 6:e235702011. View Article : Google Scholar : PubMed/NCBI
11	Bose AK, Mocanu MM, Carr RD, Brand CL and Yellon DM: Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes. 54:146–151. 2005. View Article : Google Scholar
12	Bose AK, Mocanu MM, Carr RD and Yellon DM: Glucagon like peptide-1 is protective against myocardial ischemia/reperfusion injury when given either as a preconditioning mimetic or at reperfusion in an isolated rat heart model. Cardiovasc Drugs Ther. 19:9–11. 2005. View Article : Google Scholar : PubMed/NCBI
13	Read PA, Khan FZ and Dutka DP: Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease. Heart. 98:408–413. 2012. View Article : Google Scholar
14	Read PA, Hoole SP, White PA, Khan FZ, O’Sullivan M, West NE and Dutka DP: A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans. Circ Cardiovasc Interv. 4:266–272. 2011. View Article : Google Scholar : PubMed/NCBI
15	Phong WY, Lin W, Rao SP, Dick T, Alonso S and Pethe K: Characterization of phosphofructokinase activity in Mycobacterium tuberculosis reveals that a functional glycolytic carbon flow is necessary to limit the accumulation of toxic metabolic intermediates under hypoxia. PLoS One. 8:e560372013. View Article : Google Scholar : PubMed/NCBI
16	Idrovo JP, Yang WL, Nicastro J, Coppa GF and Wang P: Stimulation of carnitine palmitoyltransferase 1 improves renal function and attenuates tissue damage after ischemia/reperfusion. J Surg Res. 177:157–164. 2012. View Article : Google Scholar : PubMed/NCBI
17	Rajaram N, Frees AE, Fontanella AN, Zhong J, Hansen K, Dewhirst MW and Ramanujam N: Delivery rate affects uptake of a fluorescent glucose analog in murine metastatic breast cancer. PLoS One. 8:e765242013. View Article : Google Scholar : PubMed/NCBI
18	Lee J and Chang JH: Facile and high-efficient immobilization of histidinetagged multimeric protein G on magnetic nanoparticles. Nanoscale Res Lett. 9:6642014. View Article : Google Scholar
19	Ji L, Zhang X, Liu W, et al: AMPK-regulated and Akt-dependent enhancement of glucose uptake is essential in ischemic preconditioning-alleviated reperfusion injury. PLoS One. 8:e699102013. View Article : Google Scholar : PubMed/NCBI
20	Moberly SP, Berwick ZC, Kohr M, Svendsen M, Mather KJ and Tune JD: Intracoronary glucagon-like peptide 1 preferentially augments glucose uptake in ischemic myocardium independent of changes in coronary flow. Exp Biol Med (Maywood). 237:334–342. 2012. View Article : Google Scholar
21	Gejl M, Søndergaard HM, Stecher C, Bibby BM, Møller N, Bøtker HE, Hansen SB, Gjedde A, Rungby J and Brock B: Exenatide alters myocardial glucose transport and uptake depending on insulin resistance and increases myocardial blood flow in patients with type 2 diabetes. J Clin Endocrinol Metab. 97:E1165–E1169. 2012. View Article : Google Scholar : PubMed/NCBI
22	Tani M and Neely JR: Role of intracellular Na⁺ in Ca²⁺ overload and depressed recovery of ventricular function of reperfused ischemic rat hearts. Possible involvement of H⁺-Na⁺ and Na⁺-Ca²⁺ exchange. Circ Res. 65:1045–1056. 1989. View Article : Google Scholar : PubMed/NCBI
23	Ferrari R, Pepi P, Ferrari F, et al: Metabolic derangement in ischemic heart disease and its therapeutic control. Am J Cardiol. 82:2K–13K. 1998. View Article : Google Scholar : PubMed/NCBI
24	Mor I, Cheung EC and Vousden KH: Control of glycolysis through regulation of PFK1: Old friends and recent additions. Cold Spring Harb Symp Quant Biol. 76:211–216. 2011. View Article : Google Scholar : PubMed/NCBI
25	Aoi W, Naito Y and Yoshikawa T: Potential role of oxidative protein modification in energy metabolism in exercise. Subcell Biochem. 77:175–187. 2014.PubMed/NCBI
26	Nguyen TD, Shingu Y, Amorim PA, Schwarzer M and Doenst T: Glucagon-like peptide-1 reduces contractile function and fails to boost glucose utilization in normal hearts in the presence of fatty acids. Int J Cardiol. 168:4085–4092. 2013. View Article : Google Scholar : PubMed/NCBI
27	Zhao T, Parikh P, Bhashyam S, Bolukoglu H, Poornima I, Shen YT and Shannon RP: Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther. 317:1106–1113. 2006. View Article : Google Scholar : PubMed/NCBI
28	Moberly SP, Mather KJ, Berwick ZC, Owen MK, Goodwill AG, Casalini ED, Hutchins GD, Green MA, Ng Y, Considine RV, et al: Impaired cardiometabolic responses to glucagon-like peptide 1 in obesity and type 2 diabetes mellitus. Basic Res Cardiol. 108:3652013. View Article : Google Scholar : PubMed/NCBI
29	Cuenda A and Rousseau S: p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim Biophys Acta. 1773:1358–1375. 2007. View Article : Google Scholar : PubMed/NCBI
30	Erdogdu O, Eriksson L, Xu H, Sjöholm A, Zhang Q and Nyström T: Exendin-4 protects endothelial cells from lipoapoptosis by PKA, PI3K, eNOS, p38 MAPK, and JNK pathways. J Mol Endocrinol. 50:229–241. 2013. View Article : Google Scholar : PubMed/NCBI
31	Xu H, Li HL, Niu ZY, Li GZ, Cao J and Jiang YD: Involvement of p38 MAPK pathway in GLP-1-induced inhibition of apoptosis in human umbilical vein endothelial cells. Sheng Li Xue Bao. 64:444–448. 2012.In Chinese. PubMed/NCBI
32	Kawasaki Y, Harashima S, Sasaki M, Mukai E, Nakamura Y, Harada N, Toyoda K, Hamasaki A, Yamane S, Yamada C, et al: Exendin-4 protects pancreatic beta cells from the cytotoxic effect of rapamycin by inhibiting JNK and p38 phosphorylation. Horm Metab Res. 42:311–317. 2010. View Article : Google Scholar : PubMed/NCBI
33	Ho RC, Alcazar O, Fujii N, Hirshman MF and Goodyear LJ: p38gamma MAPK regulation of glucose transporter expression and glucose uptake in L6 myotubes and mouse skeletal muscle. Am J Physiol Regul Integr Comp Physiol. 286:R342–R349. 2004. View Article : Google Scholar
34	Bhashyam S, Fields AV, Patterson B, Testani JM, Chen L, Shen YT and Shannon RP: Glucagon-like peptide-1 increases myocardial glucose uptake via p38alpha MAP kinasemediated, nitric oxide-dependent mechanisms in conscious dogs with dilated cardiomyopathy. Circ Heart Fail. 3:512–521. 2010. View Article : Google Scholar : PubMed/NCBI
35	Kuma Y, Sabio G, Bain J, Shpiro N, Márquez R and Cuenda A: BIRB796 inhibits all p38 MAPK isoforms in vitro and in vivo. J Biol Chem. 280:19472–19479. 2005. View Article : Google Scholar : PubMed/NCBI
36	Caverzasio J and Manen D: Essential role of Wnt3a-mediated activation of mitogen-activated protein kinase p38 for the stimulation of alkaline phosphatase activity and matrix mineralization in C3H10T1/2 mesenchymal cells. Endocrinology. 148:5323–5330. 2007. View Article : Google Scholar : PubMed/NCBI
37	Dingar D, Merlen C, Grandy S, Gillis MA, Villeneuve LR, Mamarbachi AM, Fiset C and Allen BG: Effect of pressure overload-induced hypertrophy on the expression and localization of p38 MAP kinase isoforms in the mouse heart. Cell Signal. 22:1634–1644. 2010. View Article : Google Scholar : PubMed/NCBI
38	Huisamen B, Genade S and Lochner A: Signalling pathways activated by glucagon-like peptide-1 (7–36) amide in the rat heart and their role in protection against ischaemia. Cardiovasc J Afr. 19:77–83. 2008.PubMed/NCBI
39	Vyas AK, Yang KC, Woo D, Tzekov A, Kovacs A, Jay PY and Hruz PW: Exenatide improves glucose homeostasis and prolongs survival in a murine model of dilated cardiomyopathy. PLoS One. 6:e171782011. View Article : Google Scholar : PubMed/NCBI
40	Liu Q, Anderson C, Broyde A, Polizzi C, Fernandez R, Baron A and Parkes DG: Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure. Cardiovasc Diabetol. 9:762010. View Article : Google Scholar : PubMed/NCBI
41	Arnés L, Moreno P, Nuche-Berenguer B, Valverde I and Villanueva-Peñacarrillo ML: Effect of exendin-4 treatment upon glucose uptake parameters in rat liver and muscle, in normal and type 2 diabetic state. Regul Pept. 153:88–92. 2009. View Article : Google Scholar